These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 29082795)
21. Prognostic markers and standard management of chronic lymphocytic leukemia. Stilgenbauer S Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745 [TBL] [Abstract][Full Text] [Related]
22. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial. Molica S Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582 [TBL] [Abstract][Full Text] [Related]
23. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Ladyzynski P; Molik M; Foltynski P Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118 [TBL] [Abstract][Full Text] [Related]
24. Combination therapy with the type II anti-CD20 antibody obinutuzumab. Klein C; Bacac M; Umana P; Fingerle-Rowson G Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710 [TBL] [Abstract][Full Text] [Related]
25. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Hallek M Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P; Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597 [TBL] [Abstract][Full Text] [Related]
27. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib. Cramer P; Langerbeins P; Hallek M Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018 [TBL] [Abstract][Full Text] [Related]
28. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Herishanu Y; Shaulov A; Fineman R; Bašić-Kinda S; Aviv A; Wasik-Szczepanek E; Jaksic O; Zdrenghea M; Greenbaum U; Mandac I; Simkovic M; Morawska M; Benjamini O; Spacek M; Nemets A; Bairey O; Trentin L; Ruchlemer R; Laurenti L; Stanca Ciocan O; Doubek M; Shvidel L; Dali N; Mirás F; De Meûter A; Dimou M; Mauro FR; Coscia M; Bumbea H; Szász R; Tadmor T; Gutwein O; Gentile M; Scarfò L; Tedeschi A; Sportoletti P; Gimeno Vázquez E; Marquet J; Assouline S; Papaioannou M; Braester A; Levato L; Gregor M; Rigolin GM; Loscertales J; Medina Perez A; Nijziel MR; Popov VM; Collado R; Slavutsky I; Itchaki G; Ringelstein S; Goldschmidt N; Perry C; Levi S; Polliack A; Ghia P Am J Hematol; 2020 Jun; 95(6):604-611. PubMed ID: 32096887 [TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Hallek M Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186 [TBL] [Abstract][Full Text] [Related]
31. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. Jean GW; Comeau JM Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688 [TBL] [Abstract][Full Text] [Related]
32. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322 [TBL] [Abstract][Full Text] [Related]
33. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions. Smolej L Curr Cancer Drug Targets; 2016; 16(8):710-720. PubMed ID: 27055578 [TBL] [Abstract][Full Text] [Related]
36. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Robak T; Blonski JZ; Robak P Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707 [TBL] [Abstract][Full Text] [Related]
37. Chronic lymphocytic leukemia (CLL)-Then and now. Rai KR; Jain P Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614 [TBL] [Abstract][Full Text] [Related]
38. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410 [TBL] [Abstract][Full Text] [Related]
39. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. Vitale C; Ferrajoli A Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593 [TBL] [Abstract][Full Text] [Related]
40. Update in the management of chronic lymphocytic leukemia. Maddocks KJ; Lin TS J Hematol Oncol; 2009 Jul; 2():29. PubMed ID: 19619273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]